Corticosteroids versus clobazam for treatment of children with epileptic encephalopathy with spike-wave activation in sleep (RESCUE ESES): a multicentre randomised controlled trial

克洛巴扎姆 医学 儿科 随机对照试验 奥卡西平 不利影响 麻醉 人口 癫痫 精神科 内科学 卡马西平 环境卫生
作者
Marleen M L van Arnhem,Bart van den Munckhof,Alexis Arzimanoglou,Emilio Perucca,Liisa Metsähonkala,Guido Rubboli,Marianne Søndergaard Khinchi,Anne de Saint Martin,Kerstin Alexandra Klotz,Julia Jacobs,J. Helen Cross,Irene Morales,Wim Otte,Heleen C. van Teeseling,Frans S.S. Leijten,Kees P. J. Braun,Floor E. Jansen,Anna Jansen,Lieven Lagae,Thomas Bast
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:23 (2): 147-156 被引量:8
标识
DOI:10.1016/s1474-4422(23)00409-x
摘要

Background Epileptic encephalopathy with spike-wave activation in sleep (EE-SWAS) is a rare syndrome associated with cognitive and behavioural regression. On the basis of mostly small observational and retrospective studies, corticosteroids and clobazam are often considered the most effective treatments for this syndrome. We aimed to compare cognitive outcomes of children with EE-SWAS 6 months after starting treatment with either corticosteroids or clobazam. Methods We did a multicentre, randomised controlled trial at eight tertiary referral centres for rare epilepsies in seven European countries. Children were eligible to participate if they were aged 2–12 years, were diagnosed with EE-SWAS within 6 months before inclusion, and had not been treated with corticosteroids or clobazam previously. Participants were randomly assigned (1:1) to treatment with corticosteroids (either continuous treatment with 1–2 mg/kg per day of prednisolone orally or pulse treatment with 20 mg/kg per day of methylprednisolone intravenously for 3 days every 4 weeks) or clobazam (0·5–1·2 mg/kg per day orally). The primary outcome was cognitive functioning after 6 months of treatment, which was assessed by either the intelligence quotient (IQ) responder rate (defined as improvement of ≥11·25 IQ points) or the cognitive sum score responder rate (defined as improvement of ≥0·75 points). Safety was assessed by number of adverse events and serious adverse events. Data were analysed in the intention-to-treat population, which included all children as randomised who had primary outcome data available at 6 months. The trial is registered with the Dutch Trial Register, Toetsingonline, NL43510.041.13, and the ISRCTN registry, ISRCTN42686094. The trial was terminated prematurely because enrolment of the predefined number of 130 participants was deemed not feasible. Findings Between July 22, 2014, and Sept 3, 2022, 45 children were randomly assigned to either corticosteroids (n=22) or clobazam (n=23); two children assigned clobazam dropped out before 6 months and were excluded from the intention-to-treat analysis. At the 6-month assessment, an improvement of 11·25 IQ points or greater was reported for five (25%) of 20 children assigned corticosteroids versus zero (0%) of 18 assigned clobazam (risk ratio [RR] 10·0, 95% CI 1·2–1310·4; p=0·025). An improvement of 0·75 points or more in the cognitive sum score was recorded for one (5%) of 22 children assigned corticosteroids versus one (5%) of 21 children assigned clobazam (RR 1·0, 95% CI 0·1–11·7, p=0·97). Adverse events occurred in ten (45%) of 22 children who received corticosteroids, most frequently weight gain, and in 11 (52%) of 21 children who received clobazam, most often fatigue and behavioural disturbances. Occurrence of adverse events did not differ between groups (RR 0·8, 95% CI 0·4–1·4; p=0·65). Serious adverse events occurred in one child in the corticosteroid group (hospitalisation due to laryngitis) and in two children in the clobazam group (hospitalisation due to seizure aggravation, and respiratory tract infection). No deaths were reported. Interpretation The trial was terminated prematurely, and the target sample size was not met, so our findings must be interpreted with caution. Our data indicated an improvement in IQ outcomes with corticosteroids compared with clobazam treatment, but no difference was seen in cognitive sum score. Our findings strengthen those from previous uncontrolled studies that support the early use of corticosteroids for children with EE-SWAS. Funding EpilepsieNL, WKZ fund, European Clinical Research Infrastructure Network, and Ming fund.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一叶知秋完成签到,获得积分10
1秒前
叶123完成签到,获得积分10
2秒前
量子星尘发布了新的文献求助10
3秒前
Minicoper发布了新的文献求助10
3秒前
背书强完成签到 ,获得积分10
4秒前
淡然以柳完成签到 ,获得积分10
6秒前
dolabmu完成签到 ,获得积分10
9秒前
崔崔完成签到 ,获得积分10
13秒前
SYLH应助xcxc采纳,获得10
14秒前
wp4455777完成签到,获得积分10
15秒前
十一完成签到,获得积分10
15秒前
ru完成签到 ,获得积分10
17秒前
慧木完成签到 ,获得积分10
17秒前
WW完成签到 ,获得积分10
18秒前
小高同学完成签到,获得积分10
19秒前
轻轻1完成签到,获得积分10
22秒前
23秒前
大橙子发布了新的文献求助10
27秒前
iuhgnor完成签到,获得积分10
30秒前
可夫司机完成签到 ,获得积分10
33秒前
yang完成签到,获得积分10
35秒前
一1完成签到 ,获得积分10
37秒前
jiaolulu完成签到,获得积分10
37秒前
量子星尘发布了新的文献求助10
39秒前
爆米花应助LiZhao采纳,获得10
39秒前
轻轻完成签到,获得积分10
42秒前
Orange应助jiaolulu采纳,获得10
42秒前
xcxc完成签到,获得积分10
44秒前
water应助科研通管家采纳,获得50
44秒前
44秒前
默存完成签到,获得积分10
47秒前
风中的金鱼完成签到 ,获得积分10
49秒前
橙汁完成签到,获得积分10
50秒前
普鲁卡因发布了新的文献求助10
53秒前
cora完成签到 ,获得积分10
59秒前
徐伟康完成签到 ,获得积分10
59秒前
Minicoper完成签到,获得积分10
1分钟前
科研通AI5应助普鲁卡因采纳,获得10
1分钟前
111完成签到 ,获得积分10
1分钟前
奥特曼完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022